{'fraction_non_alphanumeric': 0.024822695035460994, 'fraction_numerical': 0.0070921985815602835, 'mean_word_length': 5.451428571428571, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Levels of chemerin and asymmetric dimethylarginine (ADMA) in obese type 2 diabetic patients.

Diabetes Mellitus (D.M) has reached epidemic proportion and has become one of the most challenging health problems of the 21st century. Moreover, it is the 4th leading cause of death by disease globally, where every 10 seconds a person dies from diabetes-related causes. Obesity, insulin resistance, dyslipidemia and hypertension are associated with (T2DM) termed together as a metabolic syndrome. Mobilization of free fatty acids and secretion of certain inflammatory adipokines from adipose tissue promote insulin resistance in obese diabetics by interfere with insulin sensitivity, glucose and lipid metabolism. Chemerin, a specific adipokine, has an essential role in glucose and lipid metabolism. It plays a role in pathogenesis of obesity and T2DM also has important roles in energy metabolism, adipogenesis, and inflammation. Asymmetric dimethyl arginine (ADMA) consider a natural analogue of the essential amino acid arginine and a metabolic by-product obtained from processes of protein turnover of all human cells cytoplasm.